Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)
| Market Cap | $155.24M+37.8% |
| Revenue (ttm) | $0-100.0% |
| Net Income | $144.88M+230.4% |
| EPS | $3.41+244.4% |
| Shares Out | 43.49M |
| PE Ratio | 1.02 |
| Forward PE | n/a |
| Dividend | $0.25(7.00%) |
| Ex-Dividend Date | Jan 16, 2026 |
| Volume | 285,666 |
| Open | $3.65 |
| Previous Close | $3.69 |
| Day's Range | $3.54 - $3.71 |
| 52-Week Range | $2.52 - $5.47 |
| Beta | 1.28 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Mar 25, 2027 |
About ORMP
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 25, 2027Earnings report
$ORMP stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ORMP holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ORMP's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ORMP Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ORMP patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ORMP from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ORMP
| IWMiShares Russell 2000 ETF | $3.09M |
| IWNiShares Russell 2000 Value ETF | $1.14M |
| VTWOVanguard Russell 2000 ETF | $846.52K |
| IWCiShares Micro-Cap ETF | $380.61K |
| SILXETFMG Prime 2x Daily Junior Silver Miners ETF | $325.28K |
| VALTETFMG Sit Ultra Short ETF | $319.37K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from ORMP’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+0.0 since Oct 4Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| FSEV | Fidelity Enhanced Small Cap Value ETF | 0.05% |
Weight is the stock’s share of each fund’s holdings.
